Blood thinners for cirrhosis with portal vein clot
Part of Cancer, Digestive system clinical trials.
This study tests whether blood thinners (anticoagulants) are safe and effective for people with cirrhosis and a blood clot in the portal vein. It may also include people with liver cancer (HCC).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cirrhosis (scarring of the liver).
- You have a blood clot in the portal vein (the main vein that brings blood to your liver).
- Your liver function is Child-Pugh class A or B (mild to moderate damage).
- You may also have liver cancer (HCC), but it is not required.
- Your platelet count must be 10,000 or higher (not too low for clotting).
- Your kidney function must be good (creatinine level 1.9 or lower).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a pill (dabigatran) or a daily injection (enoxaparin) is better at preventing new blood clots in the liver vein for people with cirrhosis. Both are blood thinners, and the study wants to see which one is safer and more effective.
This study is following people with cirrhosis to see how often they get a blood clot in the liver's main vein (portal vein) and whether using blood thinners helps. If you have cirrhosis, joining this study could help doctors learn better ways to prevent and treat these clots.
This study tests whether a blood thinner called apixaban can safely prevent dangerous bleeding in people with cirrhosis (liver scarring) who have portal hypertension (high blood pressure in veins leading to the liver). The goal is to see if it reduces bleeding risk without causing excessive bleeding.
This trial tests a new oral blood thinner to prevent another bleeding episode in people with liver cirrhosis who have already had variceal bleeding and also have a clot in the portal vein. The goal is to see if it can safely reduce the risk of rebleeding.
This trial is testing whether a blood thinner called apixaban can treat a blood clot in the main vein to the liver (portal vein) that appeared more than a year after spleen surgery in people with cirrhosis. It compares apixaban to a low-dose aspirin to see if one works better with fewer side effects.
This trial tests if apixaban, a blood thinner, is more effective than aspirin at treating blood clots in the portal vein that form more than a year after laparoscopic spleen removal in people with cirrhosis and an enlarged spleen.
Hear when a new Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.